Drug Class Detail

Drug Class PDGFR-beta Inhibitor

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Linifanib ABT-869|AL-39324 CSF1R Inhibitor 22 FLT3 Inhibitor 48 KIT Inhibitor 48 PDGFR-beta Inhibitor 13 VEGFR Inhibitor (Pan) 30 Linifanib (ABT-869) is a receptor tyrosine kinase inhibitor with specificity against FLT1 (VEGFR1), CSF-1R, KDR (VEGFR2), FLT3, and KIT, which may result in inhibition of cell proliferation and tumor growth, and tumor regression (PMID: 16648571).
Orantinib SU6668|TSU-68 FGFR1 Inhibitor 21 KIT Inhibitor 48 PDGFR-beta Inhibitor 13 VEGFR2 Inhibitor 34 Orantinib (SU6668) inhibits several receptor tyrosine kinases KDR, PDGFRB, FGFR1, and KIT, thereby resulting in tumor growth inhibition (PMID: 17367541, PMID: 16144927).
Sorafenib Nexavar BAY 43-9006 CSF1R Inhibitor 22 FLT3 Inhibitor 48 KIT Inhibitor 48 PDGFR-beta Inhibitor 13 RAF Inhibitor (Pan) 17 RET Inhibitor 36 VEGFR2 Inhibitor 34 Nexavar (sorafenib) is a multikinase inhibitor with activity against several kinases, including RAF kinases, VEGFR2, VEGFR3, PDGFR-beta, KIT, FLT3, RET, and CSF1R, potentially resulting in decreased tumor growth (PMID: 18445656, PMID: 15466206, PMID: 21517818). Nexavar (sorafenib) is approved for metastatic differentiated thyroid carcinoma, hepatocellular carcinoma, and renal cell carcinoma (FDA.gov).
ZK 304709 CDK1 Inhibitor 12 CDK2 Inhibitor 16 CDK4 Inhibitor 12 CDK7 Inhibitor 9 CDK9 Inhibitor 12 PDGFR-beta Inhibitor 13 VEGFR Inhibitor (Pan) 30 ZK 304709 is a small molecule kinase inhibitor of CDKs 1, 2, 4, 7, and 9, VEGFR-1,2,3, and PDGFR-beta, which may result in inhibition of both the cell cycle and angiogenesis (PMID: 18653327).
JI-101 EPHB4 Inhibitor 6 PDGFR-beta Inhibitor 13 VEGFR2 Inhibitor 34 JI-101 inhibits KDR (VEGFR2), PDGFR-beta, and EphB4, resulting in anti-tumor activity (PMID: 26365907).
RXDX-105 AC013773|CEP-32496 ABL Inhibitor (pan) 8 ABL1 Inhibitor 4 BCR-ABL Inhibitor 23 BRAF Inhibitor 18 CRAF Inhibitor 10 KIT Inhibitor 48 PDGFR-beta Inhibitor 13 RET Inhibitor 36 VEGFR2 Inhibitor 34 RXDX-105 (CEP-32496) inhibits wild-type BRAF, BRAF V600E, c-RAF, ABL1 (and BCR-ABL), c-KIT, RET, PDGFR beta, and VEGFR2, potentially resulting in decreased tumor growth (PMID: 22319199).
Famitinib SHR1020 FLT3 Inhibitor 48 KIT Inhibitor 48 PDGFR-beta Inhibitor 13 RET Inhibitor 36 VEGFR2 Inhibitor 34 VEGFR3 Inhibitor 5 Famitinib is an analog of Sutent (sunitinib), a receptor tyrosine kinase (RTK) inhibitor, which inhibits receptor tyrosine kinases including c-Kit, VEGFR2/3, PDGFR-beta, RET, and FLT3 to reduce cell proliferation and tumor growth (PMID: 23126373).
GTP-14564 FLT3 Inhibitor 48 KIT Inhibitor 48 PDGFR-beta Inhibitor 13 GTP-14564 is a selective inhibitor of FLT3, c-Fms, c-Kit, and PDGFR-beta, which may result in reduced downstream signaling and subsequent reductions in cell proliferation and tumor growth (PMID: 12815052).
SU11652 FGFR1 Inhibitor 21 KIT Inhibitor 48 PDGFR-beta Inhibitor 13 VEGFR2 Inhibitor 34 SU11652 is an inhibitor of multiple tyrosine kinase receptors including Pdgfr-beta, Kdr (Vegfr2), Fgfr1, and Kit, which blocks pathway activation, promotes cell cycle arrest, and induces apoptosis of tumor cells (PMID: 12091352, PMID: 23216927).
Telatinib BAY 57-9352 KIT Inhibitor 48 PDGFR-beta Inhibitor 13 VEGFR2 Inhibitor 34 VEGFR3 Inhibitor 5 BAY 57-9352 (Telatinib) inhibits VEGFR2, VEGFR3, PDGFR-beta, and KIT, which may result in decreased proliferation and angiogenesis in tumors expressing these factors (NCI Drug Dictionary).
XL999 FGFR1 Inhibitor 21 FGFR3 Inhibitor 12 FLT3 Inhibitor 48 KIT Inhibitor 48 PDGFR-beta Inhibitor 13 RET Inhibitor 36 SRC Inhibitor 26 VEGFR2 Inhibitor 34 XL999 inhibits multiple tyrosine kinases including VEGFR2/KDR, FGFR1/3, PDGFR-beta, FLT3, RET, KIT, and SRC, which can result in anti-tumor activity (J Clin Oncol, 25:18s, 2007 (suppl;abstr 3591), PMID: 19581523).
EBI-907 BRAF Inhibitor 18 FGFR1 Inhibitor 21 FGFR2 Inhibitor 15 FGFR3 Inhibitor 12 KIT Inhibitor 48 PDGFR-beta Inhibitor 13 RET Inhibitor 36 EBI-907 is a multi-kinase inhibitor that inhibits BRAF V600E, FGFR1-3, RET, KIT, and PDGFRb, which results in tumor growth inhibition (PMID: 26810733).
Tandutinib MLN518|CT53518 FLT3 Inhibitor 48 KIT Inhibitor 48 PDGFR-beta Inhibitor 13 Tandutinib (CT53518) is a tyrosine kinase inhibitor of FLT3, KIT, and PDGFRbeta, which inhibits cell proliferation and induces apoptosis (PMID: 12166950, PMID: 12124172).
Molecular Profile Protein Effect Treatment Approaches